venBio Partners

Latest statistics and disclosures from venBio Partners's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are PHVS, ALMS, ALXO, HRMY, LYEL, and represent 98.78% of venBio Partners's stock portfolio.
  • Added to shares of these 1 stock: ALXO (+$6.4M).
  • Reduced shares in these 2 stocks: ALMS, ARTV.
  • venBio Partners was a net buyer of stock by $3.6M.
  • venBio Partners has $281M in assets under management (AUM), dropping by 29.72%.
  • Central Index Key (CIK): 0001776382

Tip: Access up to 7 years of quarterly data

Positions held by venBio Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for venBio Partners

venBio Partners holds 6 positions in its portfolio as reported in the March 2026 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Pharvaris N V (PHVS) 46.7 $131M 4.6M 28.25
 View chart
Alumis (ALMS) 35.6 $100M 4.5M 22.03
 View chart
Alx Oncology Hldgs (ALXO) 9.2 $26M +32% 13M 2.00
 View chart
Harmony Biosciences Hldgs In (HRMY) 4.9 $14M 489k 28.01
 View chart
Lyell Immunopharma (LYEL) 2.4 $6.8M 338k 20.06
 View chart
Artiva Biotherapeutics (ARTV) 1.2 $3.4M -18% 531k 6.44
 View chart

Past Filings by venBio Partners

SEC 13F filings are viewable for venBio Partners going back to 2019

View all past filings